| A |
|
A 1-day survey of anticoagulant use in a French general hospital
|
| Girard P., Christidis C., Cosserat J., Cathala N., Czitrom D., Le Guillou J., Lebuisson A. |
| |
|
A 4-year follow-up of adverse effects with fondaparinux treatment: results from the french pharmacovigilance survey
|
| Lillo-le louet A., Smadja D.M., Le Beller C. |
| |
|
A 9P21 genomic variant associated with premature coronary artery disease in asian indians
|
| Maitra A., Dash D., John S., Sannappa P.R., Shanker J., Rao V.S., Sridhara H., Kakkar V.V. |
| |
|
A benzodiazepines derived compound, 4-(3-chlorophenyl)-1,3-dihydronaphtho [2,3-b][1,4]diazepin-2-one (nd700c), inhibits fmlp induced superoxide anion release by activating protein phosphatase 2a in human neutrophils
|
| Liao C., Tseng C., Day Y., Chang C., Kuo S., Lin S. |
| |
|
A C.-39C > T novel point mutation in the 5′-UT region of PROS-1 gene associated with PS deficiency
|
| Labrouche S., Vergnes C., Freyburger G. |
| |
|
A case control study on platelet response to antiplatelet therapy in survivors of late stent thrombosis
|
| Winckers K., Poenitz V., van Oerle R., Noordermeer K., ten Cate H., Nilsen D.W.T. |
| |
|
A case of pericardiocentesis for hemophilia a patient with tuberculous pericardial effusion
|
| Park J., ParK Y., Lee S. |
| |
|
A case of severe acquired factor VII deficiency with anaphylaxis and disseminated intravascular coagulation following administration of different factor VII concentrates
|
| Lechner D., Machherndl-Spandl S., Knoebl P. |
| |
|
A case of severe inherited hyperhomocysteinemia in a young male having venous thromboembolism and claudication successfully treated with vitamin B6 and B9
|
| Andersen M., Dalsgaard J., Stender S. |
| |
|
A case of severe thrombocytopenia associated with pentamidine-dependent antibody specific for glycprotein IIb
|
| Heidinger K.S., Giptner A., Fischer R., Santoso S., Bein G., Sachs U. |
| |
|
A case of spontaneous heparin induced thrombocytopenia and thrombosis
|
| DeSancho M.T., Carlson K.S., Mallik A. |
| |
|
A case-controlled danish-russian comparative study of clinical outcomes in younger severe haemophilia patients treated with prophylaxis compared to those managed with on-demand treatment
|
| Ingerslev J., Lethagen S., Hvitfeldt Poulsen L., Lopatina E., Tentsova I., Yastrubinetskaya O., Plyushch O.P. |
| |
|
A chromogenic screening assay identifies thrombobotic risk factors in pre-surgery patients
|
| Johnston M., Rupwate M., McGrath J., Smirnov M., Safa O., Triscott M. |
| |
|
A clinical case of hemoglobin c disease, protein s deficiency and leukemia
|
| Aïtchafa Tadlaoui D., Touchrift C., Guechi Z. |
| |
|
A common genetic variant of factor xiii a subunit Val34leu predisposes to venous thrombosis in patients with antiphospholipid syndrome
|
| Sanak M., Iwaniec T., Dziedzina S., Musial J. |
| |
|
A common polymorphism in low-density lipoprotein receptor gene is a predictor of factor VIII activity levels and is associated with coronary artery disease
|
| Martinelli N., Lunghi B., Girelli D., Pinotti M., Marchetti G., Bisi M., Olivieri O., Manzato F., Corrocher R., Bernardi F. |
| |
|
A comparison of the prevalence of hereditary natural anticoagulant pathway defects between patients with DVT, PE and thrombosis at unusual sites
|
| Ahmadinejad M., Bashash D., Ahmadinejad T., Zolfaghari S., Tabatabaii M., Atarodi K., Seyed Mortaz L., Baluch S. |
| |
|
A complex management of anticoagulant therapy in a 70-year-old woman suffered concomitantly and subsequently from acute lifethreatening digestive bleeding, deep venous thrombosis, heparin induced thrombocytopenia and a transabdominal drainage of a liver
|
| Schiavoni M., Coluccia A., Iasella M., Bigetti L. |
| |
|
A compound heterozygous Thrombasthenia Glanzmann patient with a missense mutation and a frameshift mutation in the GPIIIA-subunit
|
| Westrup D., Pilgrimm A., Klamroth R., Scholz T., Pillitteri D., Krause M., Kirchmaier C.M. |
| |
|
A database of mutations and polymorphisms in and around the factor V gene; an update
|
| Vos H.L. |
| |
|
A disintegrin, rhodostomin, inhibits activities of LPS-treated monocytes via alphavbeta3 integrin
|
| Hsu C., Huang T. |
| |
|
A five-year experience from 848 patients tested for HIT, in a large greek hospital
|
| Theodoridis T., Kalpodimou C., El-Ali M., Cokkinos D., Christopoulou-Cokkinou V. |
| |
|
A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assays
|
| Irigoyen M.B., Primiani L., Felippo M., Candela M., Perez Bianco R., de Bracco M.E., Galassi N. |
| |
|
A fluorescence microplate assay for direct quantification of heparins and other sulfated carbohydrates
|
| Alban S., Lühn S. |
| |
|
A functional pool of P2Y12 receptors exposed upon platelet activation persists in mice treated with high dose clopidogrel, and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor
|
| Haberstock-Debic H., Andre P., Delaney S.M., Mills S., Pak Y., Phillips D.R., Conley P.B. |
| |
|
A gain-of-function mutation in the phospholipase C gamma 2 gene enhances integrin outside-in signaling and leads to a prothrombotic phenotype in mice
|
| Elvers M., Pozgaj R., Varga-Szabo D., May F., Yu P., Nieswandt B. |
| |
|
A genome wide association study to identify candidate genes for high factor VIII levels in venous thromboembolism: do abo-glycosyltransferases play an important role?
|
| Thieme F., Fiebig A., Lu T., Luxembourg B., von Eller-Eberstein H., Flesch B., Spannagl M., Lindhoff-Last E., Schreiber S., Schambeck C.M. |
| |
|
A genome wide linkage scan for thrombosis susceptibility genes identifies a novel prothrombin mutation
|
| ten Kate M.K., He C., van Schouwenburg I.M., van der Steege G., Mulder R., Wijmenga C., Mulder A.B., Kluin-Nelemans H.C., Johnson D.J.D., Huntington J.A., Ott J., van der Meer J. |
| |
|
A global test (thromboelastografy) reflect the conventional coagulogram and platelet count before liver transplantation?
|
| Ribeiro D.D., Lima A.S., Faria M.D., Caram C. |
| |
|
A glycopegylated long acting rFVIIa reduces bleeding in hemophilic rabbits
|
| Lauritzen B., Tranholm M., Ezban M. |
| |
|
A haemophilia-specific aqua-training for haemophilia patients – results of the watercise – quality of life study (WAT-QOL)
|
| von Mackensen S., Wieloch A., Zäch D., Eifrig B., Kalnins J., Zeller W. |
| |
|
A heterozygous ITGA2B R995W mutation causes constitutive activation of the αIIb/β3 receptor and results in congenital macrothrombocytopenia
|
| Kunishima S., Kashiwagi H., Ito Y., Fujimori Y., Miyajima Y., Takamatsu Y., Suzumiya J., Tomiyama Y., Saito H. |
| |
|
A high throughput study of platelet calcium response to pairwise combination from a 6-dimensional agonist space allows training of a systems biology neural network ‘platelet barcode’
|
| Chatterjee M.S., Purvis J.E., Diamond S.L. |
| |
|
A higher prevalence of hit antibodies in hemodialysis patients may be due to contaminated heparin
|
| Walenga J.M., Hoppensteadt D., Cunanan J., Adiguzel C., Iqbal O., Fareed J. |
| |
|
A history of late stent thrombosis is not associated with increased activation of the contact phase system
|
| Pönitz V., Govers-Riemslag J.W.P., ten Cate H., van Oerle R., Næsgaard P., Grundt H., Pritchard D., Larsen A., Nilsen D.W.T. |
| |
|
A hypofibrinolytic state is associated with retinal vein occlusion
|
| Cellai A., Fedi S., Lami D., Giambene B., Sodi A., Menchini U., Marcucci R., Abbate R., Gensini G., Prisco D. |
| |
|
A lyophilized lupus anticoagulant negative control prepared according to ISTH LA recommendations
|
| Sanchez D., Cueto C., Vasquez J., Bottenus R., Triscott M. |
| |
|
A mechanism for thrombin-dependent lung metastasis in patients with osteosarcoma
|
| Borensztajn K.S., Aberson H., Groot A.P., Peppelenbosch M.P., Spek A. |
| |
|
A microfludic system designed to observe platelet behavior under controlled shear in real time
|
| Conant C.G., Schwartz M., Ionescu-Zanetti C. |
| |
|
A microfluidic method for controlling the flux of platelet agonists into flowing blood
|
| Neeves K.B., Diamond S.L. |
| |
|
A microfluidic-based focal injury model provides a platform to investigate drug response regimes on thrombus formation and stability
|
| Maloney S.F., Diamond S.L. |
| |
|
A mild arterial damage facilitates downstream thrombus formation by priming platelet activation
|
| Momi S., Giannini S., Gresele P. |
| |
|
A model of how platelet factor 4 (PF4) contributes to physiologic and pathologic thrombosis
|
| Kowalska M.A., Turoczi T., Hirsch J., Rauova L., Cines D., Weiler H., Camire R., Krishnaswamy S., Poncz M. |
| |
|
A multicolor flow cytometric assay for the detection of platelet derived microparticles
|
| Mobarrez F., Antovic J., Egberg N., Hansson M., Wallén H. |
| |
|
A multi-stage/multi-design strategy identifies a new QTL for von Willebrand factor on chromosome 6 – a possible link with VTE ?
|
| Antoni G., Saut N., Luo Y., Burgos G., Heath S., Perret C., DeSuremain M., Biron-Andreani C., Schved J., Pernod G., Galan P., Zelenika D., Juhan-Vague I., Alessi M., Drouet L., Visvikis-Siest S., Lathrop M., Wells P.S., Emmerich J., Gagnon F., Morange P., Tregouet D. |
| |
|
A murine model to test antithrombotic drugs targeting human von Willebrand factor
|
| Pendu R., Marx I., Lenting P.J., Christophe O.D., Denis C.V. |
| |
|
A mutation in the kindlin-3 gene associated with combined leukocyte and platelet dysfunction
|
| Boudreaux M.K., Wardrop J., Kiklevich V., Felsburg P. |
| |
|
A negative immunoturbidometric D-dimer as a stand-alone test excludes pulmonary embolism
|
| Bates S.M., Kearon C., Julian J.A., Douketis J., Schulman S., MacKinnon B., Parpia S., Ginsberg J.S. |
| |
|
A new clinical score system for heparin-induced thrombocytopenia (HIT) diagnosis
|
| Junqueira D.R.G., Perini E., Carvalho M.G. |
| |
|
A non-human primate model of hemophilia A
|
| Waters E.K., Parker J.L., Preiss J.R., Kurz J.C., McGinness K., Chung J., Hutabarat R.M., Schaub R.G. |
| |
|
A novel analysis of initial platelet-adhesion in flowing blood
|
| Meade G.R., Lincoln B., Ricco A.J., Kent N., Basabe-Desmonts L., O’Brien S., Lee L.P., MacCraith B.D., Kenny D. |
| |
|
A novel case of selective enzymatic defect of cyclooxygenase-1 associated with haemorrhagic diathesis
|
| Pascale S., Dragani A., Mattoscio D., Ferrante E., Mucci L., Di Marzio I., Davì G., Rocca B. |
| |
|
A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis
|
| Lin K., Chung C., Huang T. |
| |
|
A novel display of patient treatment records and associated bleeding patterns for prophylaxis regimens
|
| Schroth P., Huang L., Knowlton W., Fritsch S. |
| |
|
A novel fluorometric assay of simultaneous thrombin and plasmin generation detects abnormal coagulation and fibrinolysis in plasma
|
| Grunzke M.L., Goldenberg N.A., Hathaway W.E., Jacobson L.J., Bombardier C.G., Hathaway H.A., Manco-Johnson M.J. |
| |
|
A novel homozygous missense mutation in the lman1 gene in a japanese patient with combined factors V and VIII deficiency
|
| Yamada T., Fujimori Y., Suzuki A., Miyawaki Y., Takagi A., Sano M., Matsushita T., Saito H., Kojima T. |
| |
|
A novel mechanism of inflammatory response in macrophage induced by a snake venom C-type lectin protein, aggretin
|
| Chang C., Chung C., Huang T. |
| |
|
A novel method to analyze endothelial cell protein C receptor expression in vitro
|
| Ducros E., Mirshahi S., Bermot C., Mirshahi M. |
| |
|
A novel murine hemostasis model: studies on recombinant factor VIIa and NN1731
|
| Whinna H.C., Monroe D.M. |
| |
|
A novel mutation (G2172→C) of factor V gene in a chinese family with activated protein C resistance associated with venous thromboembolism
|
| Cai H., Hua B., Fan L., Wang Q., Wang S., Zhao Y. |
| |
|
A novel mutation at the physiological termination codon of von Willebrand factor (VWF) gene produces a longer VWF protein
|
| Castaman G., Giacomelli S., Rodeghiero F. |
| |
|
A novel mutation in the VWF A1 domain causing type 2B VWD with severe chronic thrombocytopenia
|
| Bevan D.H., Cutler J., Hadonou M., Mitchell M.J. |
| |
|
A novel mutation of a highly conserved residue Asn2Asp of integrin αIIb causes glanzmann thrombasthenia
|
| Mansour W., Rosenbreg N., Haushner H., Koren A., Seligsohn U. |
| |
|
A novel role of Gab1-SHP2-PI3K complex on PECAM-1 signalling in platelets
|
| Moraes L.A., Jones C.I., Gibbins J.M. |
| |
|
A novel sinergism between epinephrine and ADP stimulates protein kinase C and Rap1b activation
|
| Lova P., Guidetti G.F., Canobbio I., Balduini C., Torti M. |
| |
|
A novel YC-1 derivative, p95wu25, inhibited angiogenesis induced by vascular endothelial growth factor
|
| Chen Y., Huang T. |
| |
|
A pediatric patient with acute stroke due to cerebral artery thrombosis
|
| Turkkan E., Pekun F., Yalcin Atay D. |
| |
|
A pharmacokinetic study: impact on thrombin generation of two recombinant factor VIII concentrates in subjects with haemophilia A
|
| Salvagno G., Astermark J., Ekman M., Franchini M., Guidi G., Lippi G., Janco R., Berntorp E. |
| |
|
A pharmacovigilance evaluation of B-Domain deleted recombinant factor VIII – interim results after 9 years
|
| Pollmann H., Westfeld M., Eifrig B., Klamroth R., Kreuz W., Lenk H., Oldenburg J., Pabinger I., Schramm W., Schwarz T., Zavazava N., Zimmermann R. |
| |
|
A phase III, double-blind, placebo-controlled study (RAISE) of eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura (ITP)
|
| Cheng G., Saleh M.N., Bussel J.B., Marcher C., Vasey S., Mayer B., Aivado M., Arning M., Stone N.L. |
| |
|
A phase IV clinical study in haemophilia B patients using an ultrapure factor IX (FIX) plasma product
|
| Mauser-Bunschoten P.E., Kleine Budde I., van der Meer F.J.M., Nováková I.R.O., Ypma P., van der Linden P.W.G., Strengers P.F.W. |
| |
|
A pivotal role of protease-activated receptor-2 in bleomycin-induced pulmonary fibrosis
|
| Borensztajn K.S., Bresser P., von der Thusen J., van den Blink B., Groot A.P., Daalhuisen J., Peppelenbosch M.P., Spek A. |
| |
|
A plasminogen deficiency attenuates atherosclerosis as a result of altered lipoprotein processing
|
| Iwaki T., Donahue D.L., Sandoval-Cooper M.J., Castellino F.J., Ploplis V.A. |
| |
|
A pooled efficacy and safety analysis of the use of antithrombin (recombinant) in hereditary at deficient patients in high-risk situations
|
| Tait C., Paidas M.J., Frieling J. |
| |
|
A positive APTT biphasic wave form is an early predictor of renal impairment in patients on the intensive care unit
|
| Sullivan K., Thachil J., Downey C., Dutt T., Harper J., Toh C.H. |
| |
|
A possible mechanism of faster onset of prasugrel – the intestine as an important contributor to the active metabolite formation in vivo
|
| Hagihara K., Kazui M., Ikenaga H., Nanba T., Fusegawa K., Kurihara A., Okazaki O. |
| |
|
A potential hot spot for unequal homologous recombination within Exon 24 of the MYH9 gene
|
| Miyazaki K., Kunishima S., Fujii W., Higashihara M. |
| |
|
A pragmatic approach for the measurement of the INR in liver patients
|
| Riddell A.F., Calvaruso V., Tuddenham E.G., Burroughs A., Gatt A. |
| |
|
A predictive model for indentifying children at risk for symptomatic thromboembolism during acute lymphoblastic leukemia treatment – results of a multicenter cohort study
|
| Flege S., Mitchell L., Kenet G., Fruhwald M., Schobess R., Nowak-Gottl U. |
| |
|
A probabilistic cost-effectiveness analysis for deep-vein thrombosis prophylaxis enoxaparin versus no intervention in oncology patients following surgery in Brazil
|
| de Meis E., Schluckebier L., Fernandes R.A., Bernardina E., Levy R.A., Quintella F.F. |
| |
|
A progress report on the prospective study for the diagnosis of DIC
|
| Wada H., Kawasugi K., Kushimoto S., Tsuyoshi H., Uchiyama T., Seki Y., Okamoto K., Okamura T., Madoiwa S., Gando S. |
| |
|
A prospective analysis of plasma tissue factor in patients with ovarian tumors
|
| Amirkhosravi A., Bigsby IV G., Coll E., Desai H., Amaya M., Robles L., Faust P., Drexler A., Langer F., Reyes E., Francis J. |
| |
|
A prospective blind study on diagnosis and clinical risk of isolated calf deep vein thrombosis in symptomatic outpatients (the calthro study; NCT00816920)
|
| Palareti G., Cosmi B., Lessiani G., Rodorigo G., Guazzaloca G., Brusi C., Conti E., Filippini M., Sartori M., Legnani C. |
| |
|
A prospective cohort study on the absolute risk of venous thromboembolism in asymptomatic subjects with hereditary deficiencies of protein S, protein C or antithrombin
|
| Mahmoodi B.K., Brouwer J., ten Kate M., Lijfering W., Veeger N., Kluin-Nelemans H., van der Meer J. |
| |
|
A prospective study about von Willebrand diasese in women with obstetric and gynaecological problems
|
| Gagliano F., Amodeo R., Martorana A., Guido R., Dantona G. |
| |
|
A prospective study of quantitative D-dimer and endogenous thrombin potential measurements in individuals stopping oral anticoagulants for acute venous thromboembolism; role in predicting risk of recurrent thrombotic events
|
| Green S.P., Hynes E., Knaggs K., Hanley J., Kesteven P., Talks K.L. |
| |
|
A prospective, randomized trial of daily prophylaxis in hemophilia
|
| Berntorp E., Lindvall K., Astermark J., Kampf L., Steen Carlsson K., Ljung R., Björkman S. |
| |
|
A quantitative model for the humoral coagulation network
|
| Isbister G.K., Wajima T., Duffull S.B. |
| |
|
A randomized, prospective, open-label study on distal vein thrombosis (low-molecular-weight heparin vs. warfarin for 6 weeks): the todi study
|
| Ghirarduzzi A., Camporese G., Siragusa S., Imberti D., Bucherini E., Landini F., Ageno W., Prandoni P. |
| |
|
A rapid assay to distinguish between beta2-glycoprotein i dependent and prothrombin dependent lupus anticoagulant
|
| van Os G.M.A., Meijers J.C.M., Urbanus R.T., Derksen R.H.W.M., de Groot P.G. |
| |
|
A rapid, sensitive FRET activity assay using Alexa488/vWf84, a novel substrate for quantification of ADAMTS13 in plasma
|
| Guinto E.R., Smirnov M., Fryer H.J.L., Hoecke C.J., Greenfield R.S. |
| |
|
A reliable marker of endothelial cell dysfunction and vascular damage: legend or reality?
|
| Corinaldesi G., Corinaldesi C. |
| |
|
A retrospective and prospective single centre study on applicability of the proposed wraige classification for subtypes of arterial ischemic stroke (AIS) in children
|
| Saracco P., Agostini M., Tocchet A., Vittorini R., Licari V., Marinaccio C., Pagana L., Bobba B., Bassi B. |
| |
|
A retrospective case control study on the role of hypercoagulability in late stent thrombosis
|
| Winckers K., Poenitz V., van Oerle R., Spronk H., Hackeng T.M., Nilsen D.W.T., ten Cate H. |
| |
|
A retrospective claims database analysis of haemophilia patients with inhibitors focusing on cost outliers
|
| Bonnet P.O. |
| |
|
A retrospective review of bidging therapy in a community based out patient anticoagulation clinic
|
| Beaudoin S., Johnson S.C., Mukon M., Kapur D., Dhami M., Slater D.E. |
| |
|
A risk assessment model for the identification of hospitalized medical patients at risk of venous thromboembolism
|
| Barbar S., Tormene D., Perlati M., Brandolin B., Simioni P., Pagnan A., Prandoni P. |
| |
|
A role for ADAP in regulating integrin alpha2beta1 in platelets
|
| Jarvis G.E., Hamaia S., Bihan D., Rudd C.E., Farndale R.W. |
| |
|
A role for micro-RNA in the regulation of human VAMP8 expression and platelet reactivity
|
| Kondkar A., Nagalla S., Bray M., Shaw C., Leal S., Jin Y., Whiteheart S., Bray P.F. |
| |
|
A role for SHIP1 in platelet internal contraction via the control of actomyosin and microtubule dynamics
|
| Gratacap M., Severin S., Chicanne G., Martin V., Allart S., Eckly A., Plantavid M., Payrastre B. |
| |
|
A role for the endothelial tetraspanin Tspan18 in calcium signalling
|
| Colombo D., Heath V.L., Herbert J.M.J., Bicknell R., Watson S.P., Tomlinson M.G. |
| |
|
A role of platelet membrane microdomains in CLEC-2-mediated signal transduction
|
| Suzuki-Inoue K., Inoue O., Ozaki Y. |
| |
|
A role of the endothelial P2Y1 receptor in monocyte adhesion to and transmigration across murine microvascular endothelial cells in vitro
|
| Zerr-Fouineau M., Hechler B., Lanois I., Cazenave J., Gachet C. |
| |
|
A sensitized suppressor screen to identify modifier genes for factor V Leiden-dependent thrombosis in the mouse
|
| Westrick R.J., Manning S.L., Zhu G., Siemieniak D.R., Ginsburg D. |
| |
|
A series of hereditary factor deficiencies presenting with bleeding at a pediatric hematology unit
|
| Pekun F., Turkkan E., Guler S., Korkmaz G. |
| |
|
A serious problem in new reagent lots of beta(2)- glycoprotein I IgG assay
|
| Javela K., Mustonen P. |
| |
|
A shift from low numbers of cellular microparticles with high specific procoagulant activity to high numbers with low specific procuagulant activity during chemotherapeutic leukemia treatment: behaviour of blast-derived microparticles in a phospholipid- A
|
| Trappenburg M.C., van Schilfgaarde M., Molenaar P.J., Terpstra W.E., Leyte A. |
| |
|
A significant increase in venous thromboembolism in hospitalized children in the USA from 2001 to 2007
|
| Raffini L.J., Huang Y., Witmer C., Feudtner C. |
| |
|
A single causative mutation in the promoter region of F8 gene associated with FVIII inhibitor development
|
| Costa C., Repesse Y., Gautier P., Goossens M., Borel-Derlon A. |
| |
|
A single centre experience of prophylactic rFVIIA in paediatric patients with severe haemophilia and inhibitors
|
| Breen K.A., Kavanagh M., Kelly I., Nolan B., Regan I., McMahon C. |
| |
|
A small molecule inhibitor of P2Y1 blocks adp-induced aggregation but not shape change via an allosteric mechanism
|
| Mairuhu R., Dowal L., Dilks J.R., Blaira P., Flaumenhaft R. |
| |
|
A structural basis for the inhibition of Src-family kinase activity by dietary flavonoids
|
| Wright B., Lovegrove J.A., Gibbins J.M. |
| |
|
A study on the pathophysiology of preeclampsia – the platelet dysfunction. a series of 3 cases
|
| Onisai M., Vladareanu R., Vladareanu A., Bumbea H., Radesi S., Ciorascu M., Nicolescu A., Voican I. |
| |
|
A surplus antiplatelet action of clopidogrel in coronary artery disease patients treated with aspirin
|
| Dropinski J., Sanak M., Jakiela B., Wegrzyn W., Musial J., Szczeklik A. |
| |
|
A synergistic role of combination of ApoB and hHSP60 epitopes in regression of atherosclerotic lesion
|
| Lu X., Endresz V., Xia M., Chen D., Qi G., Faludi I., Burián K., Csanadi A., Miczák A., Gonczol E., Kakkar V. |
| |
|
A systematic review of the effects of hemophilia and von Willebrand disease on arterial trombosis
|
| Rafi S., Zwiers M., Peters M., van der Meer J., Rosendaal F.R., Buller H.R., Kamphuisen P.W. |
| |
|
A thrombin generation test in FVIII-deficient mouse plasma
|
| Dockal M., Hartmann R., Fries M., Panholzer E., Schiviz A., Muchitsch E.M., Scheiflinger F. |
| |
|
A tissue plasminogen activator deficiency enhances adenoma growth and angiogenesis in a model of familial adenomatous polyposis
|
| Ploplis V.A., Tipton H., Chapman S., Sandoval-Cooper M.J., Balsara R.D., Carmony A., Menchen H., Castellino F.J. |
| |
|
A unique recombinant plasmin molecule lacking kringles 2–5 exhibits comparable hemostatic safety and efficacy as full-length, plasma-derived plasmin
|
| Marder V.J., Manyak S., Gruber T., Hunt J., Bromirski J., Goyal A., Scuderi P., Petteway Jr S.R., Novokhatny V. |
| |
|
A VTE prevention program implemented by a VTE nurse specialist leads to a marked and sustained improvement in appropriate VTE prophylaxis
|
| Collins R.D., Gibbs H., Gibbs J., Schluter J., Tewhatu L. |
| |
|
Abdominal vein thrombosis as the first clinical feature of myeloproliferative syndrome
|
| Zawilska K.M., Jamrozek-Jedlinska M.M., Grzywacz A.M. |
| |
|
Aberrant diagnostic pattern in a Brazilian patient with severe hemophilia A explainable by an int1h-related inversion combined with a deletion in F8
|
| Mühle C., Pio S.F., Zouain D., Correa G., Rezende S.M. |
| |
|
Abnormal megakaryocyte and proplatelet formation in megakaryocyte-restricted MYH9 inactivation
|
| Eckly A., Strassel C., Freund M., Cazenave J., Lanza F., Gachet C., Léon C. |
| |
|
Abnormalities in fibrinolytic factors contribute to hypercoagulable states and are quantifiable utilizing the overall haemostatic potential (OHP) assay
|
| Curnow J.L., Morel-Kopp M.C., Ward C.M. |
| |
|
ABO blood group as a risk factor for venous thrombosis
|
| Adamczuk Y.P., Iglesias Varela M.L., Martinuzzo M.E., Cerrato G.S., Forastiero R.R. |
| |
|
ABO blood group genotyping and venous thrombosis in Brazilian women using estrogen
|
| Santos M.S., Guimarães D.A.M., Paiva S.G., Sabino A.P., Carvalho M.G., Ribeiro D.D., Gomes K.B., Dusse L.M.S., Fernandes A.P. |
| |
|
ABO blood group polymorphisms in Brazilian patients with vascular arterial disease
|
| Fernandes A.P., Sabino A.P., Ribeiro D.D., Lages G.G., Santos M.S., Gadelha T., Dusse L.S., Carvalho M. |
| |
|
ABO Blood group, D-dimer and factor VIII levels in post menopausal women using hormone replacement therapy
|
| Guimarães D.A.M., Santos M.S., Rios D.R.A., Piva S.G., Cardoso J.E., Gomes K.B., Franco R.M., Teixeira G.S., Dusse L.M.S., Carvalho M., Fernandes A. |
| |
|
Absence of residual vein thrombosis after an episode of idiopathic deep vein thrombosis: short-term anticoagulation is safe. the “extended dacus study”
|
| Siragusa S.M., Malato A., Saccullo G., Pizzo G., Caramazza D., Lo Coco L., Baiardi G., Milio G., Pinto A. |
| |
|
Absolute quantitation of VWF mRNA from human normal platelets
|
| Zapata V.A., Kempfer A.C., Carrivale M.A., Paiva Palomino J.H., Vellicce A., Powazniak Y.P., Lazzari M.A. |
| |
|
Accelerated thrombosis in a mouse model with impaired mitochondrial signaling
|
| Jobe S.M., Clemmons W. |
| |
|
Accumulation of therapeutic factor VIII in the marginal zone of the spleen of factor VIII-deficient mice
|
| Delignat S., Navarrete A., Dasgupta S., Repesse Y., André S., Meslier Y., Teyssandier M., Kaveri S., Lacroix-Desmazes S. |
| |
|
Accuracy and precision of INRATIO 2 – a new generation of a point of care coagulometer
|
| Engelsen J., Dalsgaard Nielsen J. |
| |
|
Accurate quantification of microparticles by flow cytometry : important issues
|
| Mullier F., Dogné J.M., Bailly N., Cornet Y., Robert S., Chatelain B. |
| |
|
ACE D/-240T haplotype modulates the predisposition to peripheral arterial disease
|
| Fatini C., Sticchi E., Abdihakim A., Sofi F., Romagnuolo I., Pratesi G., Pulli R., Pratesi C., Abbate R., Gensini G. |
| |
|
ACE inhibition reduces monocyte Mfg-e8 and MCP-1 expression in rats with chronic heart failure
|
| Pfrang J., Fraccarollo D., Bauersachs J., Schaefer A. |
| |
|
Acquired Bernard Soulier Syndrome: successful management with plasmapheresis in the peri-operative setting
|
| Nagalla S., Singh P., Pullen G., Herman J.H., Bray P.F. |
| |
|
Acquired factor X (FX) deficiency, chronic lymphocytic leukaemia (CLL) and amyloidosis (A)
|
| Bastos L.A., Grosso S.H., Ingratti M., Sanchez Luceros A., Rey I., Rodriguez A., Meschengieser S., Blanco A., Lazzari M. |
| |
|
Acquired factor X deficiency: difficulties to establish etiologic diagnosis
|
| Kaci Z., Ahmidatou H., Zidani N., Chennoukh K., Berkouk Y., Belhani M. |
| |
|
Acquired factor XIII deficiency in a child
|
| Hu C.Y., Saksena R., Ricafort R., Manwani D. |
| |
|
Acquired haemophilia A in china:review and meta-analysis focused on clinical characters and management
|
| Zheng C., Wu J., Ding K., Zhu W., Cai X. |
| |
|
Acquired haemophilia: descriptive data of the European acquired haemophilia registry (EACH2)
|
| Levesque H., Collins P., Baudo F., Huth-Kuhne A., Knoebl P., Marco P., Nemes L., Tengborn L. |
| |
|
Acquired inhibitors of blood coagulation: the Venezuelan National Hemophilia Center experience
|
| Boadas A., Reyes C., Mijares M., de Bosch N., Echenagucia M., Torres A., Borges R., Ruiz-Saez A. |
| |
|
Acquired severe biological von Willebrand syndrome without bleeding: role of platelet von Willebrand factor?
|
| Chollet M.E., Caron C., Boval B., Bellucci S., Bal dit Sollier C., Hadj-Ali A., Yakoubi M., Soria C., Drouet L. |
| |
|
Acquired von Willebrand syndrome in patients with multiple myeloma
|
| Djunic I.S., Elezovic I., Milosevic Jovcic N., Ilic V., Antic D., Vidovic A., Tomin D. |
| |
|
Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas
|
| Scepansky E., Othman M., Smith H. |
| |
|
Activated factor X cleaves factor VIII at arginine 562 limiting its cofactor efficiency
|
| Plantier J., Rolli V., Ducasse C., Dargaud Y., Enjolras N., Boukerche H., Négrier C. |
| |
|
Activated factor X cleaves PAR1 and mediates signaling dependent on binding to the endothelial protein C receptor
|
| Schuepbach R.A., Riewald M. |
| |
|
Activated protein C (APC) inhibits inflammation and apoptosis by regulating endoplasmic reticulum (ER) stress
|
| Toltl L.J., Austin R.C., Liaw P.C.Y. |
| |
|
Activated protein C (APC) promotes proliferation of rat keratinocytes via activation of protease-activated receptor1 (PAR1) and endothelial protein C receptor (EPCR)
|
| Kiseleva E.V., Gorbacheva L.R., Davydova O.N., Ishiwata S., Strukova S.M. |
| |
|
Activated protein C cofactor function of protein S: a critical role for the EGF1-like domain
|
| Andersson H.M., Arantes M.J., Crawley J.T.B., Luken B.M., Lane D.A., Rezende S.M. |
| |
|
Activated protein c inhibits histamine release and activation of nf-kb in mast cell from rats under normal conditions and acute inflammation
|
| Rusanova A., Ishiwata S., Strukova S. |
| |
|
Activated protein C prevents the NF-κB activation at glutamate- and thrombin- induced toxicity
|
| Strukova S., Gorbacheva L., Savinkova I., Pinelis V., Ishiwata S., Reiser G. |
| |
|
Activated protein C regulates cardiomyocyte function via EPCR and PAR1
|
| Dutt T., Dubuis E., Perez-Casal M., Wang G., Hart G., Toh C. |
| |
|
Activated thrombin activatable fibrinolysis inhibitor (TAFIA) levels in high pregnancy
|
| Peetz D., Dickemann D., Interthal C., Rolfes E., Schinzel H. |
| |
|
Activation and inactivation rates of a new recombinant FVIII (N8) are similar to FVIII expressed as full length molecule
|
| Balling K.W., Kjalke M. |
| |
|
Activation and injury of cultured endothelial cells in hypoxia and reoxygenation. Effects of extracellular pH
|
| Antonova O.A., Loktionova S.A., Romanov Y.A., Shustova O.N., Mazurov A.V. |
| |
|
Activation of antithrombin by two sites mutations
|
| Koide T., Kawajiri H., Ooe E., Shoya Y. |
| |
|
Activation of coagulation by antineoplastic drugs for multiple myeloma
|
| Nishio M., Hoshi A., Chung J., Matsumoto A., Koyama T. |
| |
|
Activation of coagulation in sickle cell trait; possible role for circulating microparticle tissue factor
|
| Key N.S., Amin C., Chang J.Y., Adam S., Kutlar A., Hulkower B., Esserman D., Mackman N., Ataga K.I. |
| |
|
Activation of coagulation system and endothelial microparticles in children with henoch schonlein purpura
|
| Sirachainan N., Reakatanan W., Chunharas A., Kardkasam P., Porntrasertsud N., Tapaneya-Olarn W., Treepongkarune S., Chuansumrit A. |
| |
|
Activation of fibrinolysis and bleeding history in patients with systemic mastocytosis
|
| Seidel H., Hertfelder H.J., Alfter K., Kolck U.W., von Kügelgen I., Homann J., Oldenburg J., Molderings G.J. |
| |
|
Activation of haemostasis in elderly patients with chronic heart failure
|
| Shmeleva V.M., Semenova O.N. |
| |
|
Activation of prekallikrein by contaminated heparins, isolated contaminant and related hypersulfated chondroitin sulfate preparations: pharmacologic implications
|
| Hoppensteadt D., Iqbal O., Messmore H., Adiguzel C., Bansal V., Fareed J. |
| |
|
Activation of the hemostatic system and endothelial dysfunction in chronic cocaine consumers: association with brain perfusion defects
|
| Pereira J., Sáez C.G., Olivares P., Moreno N., Cabrera M.J., Panes O., Hidalgo P., Massardo T., Pallavicini J., Jaimovich R., Quintana J.C., Mezzano D. |
| |
|
Activation of the intrinsic coagulation proteins and the risk of arterial thrombosis in young women
|
| Siegerink B., Govers-Riemslag J.W.P., Rosendaal F.R., ten Cate H., Algra A. |
| |
|
Activation of the intrinsic pathway of blood coagulation by particulate matter in vitro
|
| Kilinc E., Spronk H.M.H., Gosens I., van Oerle R., Govers-Riemslag J.W.P., Gerlofs-Nijland M.E., Cassee F.R., ten Cate H. |
| |
|
Activation of tissue factor (TF)-triggered coagulation by protein disulfide isomerase (PDI)
|
| Engelmann B. |
| |
|
Activation of tissue factor-dependent clotting pathway in human platelets is agonist-specific, uses src-Lyn signaling pathway, is not inhibited by TFPI and is not induced by PKC-signaling agonists
|
| Mezzano D., Valenzuela G., Matus V., Pereira J., Panes O. |
| |
|
Active platelet-derived TAFI attenuates platelet-rich thrombus lysis in vitro
|
| Schadinger S.L., Boffa M.B. |
| |
|
Active von Willebrand factor (VWF) in plasma of sickle cell patients is an indicator of disease severity
|
| Chen J., Hobbs W., Le J., Lenting P., de Groot P.G., Lopez J.A. |
| |
|
Acute ischemic cerebrovascular accident (CVA) after bevacizumab therapy. Case report & review of the literature
|
| Biswar R.M., Jubelirer S.J., Rosencrance J.G. |
| |
|
Acute promyelocytic leukemia treated with idarubisin complicated by focal segmental glomerulosclerosis
|
| Celkan T., Baris S., Baris M., Dogru O., Ozdemir N., Albayram S., Kilicaslan I. |
| |
|
Acute traumatic coagulopathy is dependent on both injury severity and shock: clinical and experimental validation
|
| Frith D., Stanworth S., Gaarder C., Maegele M., Goslings C., Johansson P.I., Allard S., Cohen M.J., Pearse R.M., Thiemermann C., Brohi K. |
| |
|
Acute traumatic coagulopathy: functional characterisation by rotational thrombolelastometry
|
| Davenport R.A., Allard S., Coates A., Thiemermann C., Pasi J., Pearse R., Brohi K. |
| |
|
ADAMTS-13 activity and antigen in commercial von-Willebrand-factor (VWF) concentrates
|
| Scharrer I., Vigh T., Böhm-Weigert M. |
| |
|
ADAMTS-13 activity is decreased in children with beta-thalassemia
|
| Sosothikul D., Kuwatjanakul P., Kittikalayawong Y., Bubpachart C., Seksarn P. |
| |
|
ADAMTS13 activity, ADAMTS13 and vWF Antigen concentration and the risk of myocardial infarction
|
| Vetr H., Geiter S., Graf M., Laemmle B., Redondo M., Binder B.R. |
| |
|
ADAMTS13 activity, race, and age as predictors of exacerbation in patients with idiopathic TTP
|
| Cataland S.R., Yang S., Witkoff L., Kraut E.H., Lin S., George J.N., Wu H.M. |
| |
|
ADAMTS13 and vwf antigens assessment in patients undergoing hemodialysis with and without thrombotic complications
|
| Rios D.R.A., Carvalho M.G., Guimarães D.A., Silva A.C.S., Lima E.M., Souza R.A., Dusse L.M.S. |
| |
|
ADAMTS13 in thrombotic thrombocytopenic purpura (TTP) evaluation of 11 cases reveals 2 new mutations
|
| Fidalgo T., Martinho P., Salvado R., Sevivas T., Silva Pinto C., Marques D., Gonçalves E., Martins N., Ribeiro M. |
| |
|
Adamts13 levels in HIV infected patients with and without TTP
|
| Meiring M., Van Staden B., Van Hoorelbeke K., Deckmyn H., Badenhorst P. |
| |
|
ADAMTS13 metalloprotease domain subsites control cleavage site specificity
|
| de Groot R., Lane D.A., Crawley J.T.B. |
| |
|
Additional catheter-directed venous thrombolysis in iliofemoral deep vein thrombosis; short-term results from the cavent study, a multicenter, randomized controlled trial
|
| Enden T.R., Slagsvold C.E., Kl⊘w N.E., Sandset P.M. |
| |
|
Adeno-associated virus vector expression of large genes is enhanced by proteasome inhibitors as modeled in hemophilia A mice and dogs
|
| Monahan P.E., Sun J., Lothrop Jr C.D., Samulski R.J. |
| |
|
Adequacy of venous thromboprophylaxis in acutely ill medical patients (impart): preliminary report of a multisite comparison of different decision support systems
|
| Nendaz M.R., Chopard P., Lovis C., Doerffler J., Kucher N., Asmis L., Spirk D., Bounameaux H. |
| |
|
ADF / n-cofilin-dependent actin turnover is essential for platelet formation
|
| Bender M., Elvers M., Pleines I., Gurniak C., Krohne G., Witke W., Nieswandt B. |
| |
|
Adhesion, proliferation and migration of human umbilical vein endothelial cells on fibrinogen gamma A and gamma’
|
| Cheung E.Y., Weijers E.M., Koolwijk P., de Maat M.P. |
| |
|
Adhesives properties of a hemolin from lonomia obliqua caterpillar bristles and mechanisms of activation of human factor X
|
| Flores M.P., Ramos O.H., Chudzinski-Tavassi A.M. |
| |
|
Adiponectin-dependent effects of pitavastatin on platelet-derived microparticles, soluble CD40 ligand and MCP-1 in hyperlipidemic patients
|
| Inami N., Nomura S., Shouzu A., Omoto S., Shimazu T., Satoh D., Kajiura T., Yamada K., Iwasaka T. |
| |
|
Administration of antithrombin concentrate and effect on anticoagulation
|
| Bauman M.E., Bauman M.L., Black K.L., Bajzar L., Massicotte M.P. |
| |
|
ADP-mediated aggregation as a pharmacodynamic assay underestimates the antithrombotic activity of elinogrel, a competitive, reversible P2Y12 inhibitor, relative to clopidogrel
|
| Conley P.B., Andre P., Stephens G., Haberstock-Debic H., Jurek M., Gretler D., Phillips D.R. |
| |
|
Adsorption-induced fibrinogen self-assembly: evidence of essential alpha-C domain and ‘A’ knob roles
|
| Galanakis D.K., Koo J., Kudryk B., Rafailovich M. |
| |
|
Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy
|
| Goldhaber S.Z. |
| |
|
Advances in ITP
|
| Cines D.B. |
| |
|
Adverse outcomes following non-cerebral arterial thromboses in neonates: a case-series report
|
| Franco J., Williams S., Chaudry G., Connonly B., Castle D., Brandao L.R. |
| |
|
Afibrinogenaemia; an Iranian experience
|
| Baghaipour M.R. |
| |
|
Age is more important to predict carotid stenosis amenable of surgical correction than focal neurological symptoms
|
| Verlato F., Verlato G., Marzolo M., Camporese G., Rosso F., Busonera F., Nardi M., Andreozzi G. |
| |
|
Age modulates the level of clinical risk associated with clodipogrel biological non-responsiveness in cardiovascular patients: a meta-analysis on 14 prospective studies
|
| Combescure C., Fontana P., Mallouk N., Berdague P., Labruyere C., Barazer I., Gris J., Fabbro-Peray P., Reny J.L. |
| |
|
Age-adjusted d-dimer cut-off levels increase the clinical utility of ruling out pulmonary embolism in elderly patients
|
| Douma R.A., le Gal G., Söhne M., Righini M., Kamphuisen P.W., Perrier A., Kruip M.J.H.A., Bounameaux H., Büller H.R., Roy P.M. |
| |
|
Age-dependent impairment of number and angiogenic potential of adipose tissue – derived progenitor cells
|
| Madonna R., Renna F., Cellini C., Cotellese R., Picardi N., Innocenti P., De Caterina R. |
| |
|
Age-related differences in in vivo UFH response in children
|
| Newall F.H., Ignjatovic V., Johnston L., Lane G., Summerhayes R., Monagle P. |
| |
|
Age-related differences in the binding of unfractionated heparin (UFH) to plasma proteins
|
| Straka E., Ignjatovic V., Summerhayes R., Monagle P. |
| |
|
Age-related reference ranges of C1-INH activity and antigen are important for early diagnosis in paediatric HAE patients
|
| Kreuz W., Rusicke E., Martinez-Saguer I., Aygören-Pürsün E., Klingebiel T. |
| |
|
Aggressive therapies for DVT and PE
|
| Wakefield T.W. |
| |
|
Agreement of perfusion scintigraphy and CT-angiography in detecting residual thromboemboli after pulmonary embolism
|
| Dentali F., Donadini M., Cosmi B., Bozzato S., Squizzato A., Neri C., Ageno W. |
| |
|
Air travel and risk of venous thromboembolism: a community-based study
|
| MacCallum P.K., Mt-Isa S., Whyte K., Letley L., Martin J., Vickers M.R., Hennessy E.M., Ashby D. |
| |
|
Akt regulates weak-agonist mediated Rap1b activation via a GSK-3 independent signalling pathway in platelets
|
| Sumathipala R.N., Patel K.V., Rahman S., Nishino Y., Webb I.G., Rangarajan S., Kaiser W.J., Gibbins J.M., Patel Y.M. |
| |
|
Ala312Thr polymorphism is not associated with changes in clot structure in a recombinant system: pitfalls in analyzing plasma-purified protein
|
| Standeven K.F., Dolling S., Phoenix F.P., Gersh K., Weisel J.W., Ariens R.A.S., Ajjan R.A. |
| |
|
Alignment to prophylaxis guidelines and occurrence of venous thromboembolism after total hip and knee replacement
|
| Selby R., Borah B., McDonald H., Henk J., Crowther M., Wells P. |
| |
|
Alimentary lipemia is associated with increased plasma VIIaAT concentration and thrombin generation
|
| Silveira A., Carlo A., Woodhams B.J., Hamsten A. |
| |
|
All round utility of factor VIII deficient plasma with vWF
|
| Xia J., Patel H., Kung C., Triscott M. |
| |
|
Allelic variants of human factor VIII in brazilian patients with severe hemophilia A and correlation with the risk of inhibitor
|
| Santos A., Damian G., Siqueira L.H., de Paula E.V., Annichino-Bizzacchi J.M., Ozelo M.C. |
| |
|
Allogeneic mesenchymal stem cells confer vascular protection after balloon angioplasty in rabbit carotids
|
| Liu P., zhang L., Liao W., Du W., Gu D., Liu M., Xu J., Lu S., Xing W., Yang S., Zhou B., Han Z. |
| |
|
Alpha IIb carries a new polymorphism, in a+, involved in neonatal thrombocytopenia
|
| JALLU V., Dusseaux M., Granier D., Kaplan C., Bertrand G. |
| |
|
Alpha1-antitrypsin pittsburgh in a family with bleeding tendency
|
| Hua B., Fan L., Liang Y., Zhao Y., Tuddenham E.G.D. |
| |
|
Alpha-6 integrin subunit plays a major role in proangiogenic properties of endothelial progenitor cells
|
| Bouvard C., Gafsou B., Dizier B., Galy-Fauroux I., Lokajczyk A., Boisson-Vidal C., Fischer A.M., Helley D. |
| |
|
Alpha-linolenic acid diminishes atherothrombosis, reduces red cell arachidonic acid and endothelial tissue factor expression
|
| Matter C.M., Lohmann C., Tanner F.C., Holy E.W., Richter E.K., Leiber F., Lüscher T.F., Forestier M., Beer J.H. |
| |
|
Alteration of the lmwhs inhibitory effect on thrombin generation by different histological types of cancer cells. An in vitro study
|
| Galea V., Mbemba M., Khaterchi A., Prengel C., Bernaudin J., Hatmi M., Elalamy I., Gerotziafas G.T. |
| |
|
Alterations in the external redox potential of the platelet environment impacts on platelet reactivity
|
| Neill S.O., Murphy D. |
| |
|
Alterations of platelet function in patients with chronic myeloid leukemia
|
| Popov V., Bumbea H., Vladareanu A., Saftoiu C., Radesi S., Nicolescu A., Savopol T., Kovacs E. |
| |
|
Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism
|
| Undas A., Zawilska K., Ciesla-Dul M., Lehmann-Kopydlowska A., Skubiszak A., Ciepluch K., Tracz W. |
| |
|
Altered megakaryocytopoiesis in von Willebrand type 2B disease
|
| Nurden A.T., Federici A.B., Nurden P. |
| |
|
Altered reference ranges for protein C and protein S during early pregnancy: implications for diagnosis of their deficiency during pregnancy
|
| Said J.M., Ignjatovic V., Monagle P., Walker S.P., Higgins J.R., Brennecke S.P. |
| |
|
Altered trafficking of bone marrow-derived CXCR4+ progenitor cells following cardiac surgery with the use of cardiopulmonary bypass
|
| Dotsenko O., Xiao Q., Xu Q., Jahangiri M. |
| |
|
Alternative anticoagulation with fondaparinux in pregnant patients with heparin-intolerance
|
| Schindewolf M., Linnemann B., Luxembourg B., Lindhoff-Last E. |
| |
|
Alternatively spliced tissue factor promotes angiogenesis through integrin ligation
|
| van den Berg Y.W., van den Hengel L.G., Myers H.R., Ayachi O., Jordanova K., Ruf W., Spek A.C., Reitsma P.H., Versteeg H.H. |
| |
|
ALX-0081 a novel anti-thrombotic: first results of a multiple dose phase 1 study in patients with stable angina undergoing PCI
|
| Holz J., Bartunek J., Barbato E., Vercruysse K., Pullan S., Heyndrickxs G. |
| |
|
Amino acid residues R660, R661 and Y662 within the spacer domain of ADAMTS13 are essential for recognition and cleavage of von Willebrand factor
|
| Jin S., Zheng X. |
| |
|
Amyloid precursor protein proteolysis in human platelets is regulated by calmodulin
|
| Canobbio I., Catricalà S., Cipolla L., Balduini C., Torti M. |
| |
|
An accurate and routinely adapted enzyme-linked immunosorbent assay for type 2N von Willebrand disease diagnosis
|
| Caron C., Ternisien C., Wolf M., Fressinaud E., Goudemand J., Veyradier A. |
| |
|
An alternative diagnostic strategy with lower radiatioin risk in young women with suspected pulmonary embolism
|
| Douma R.A., Kamphuisen P.W., Rijnders A.J.M., Hendrickx B., ten Wolde M., Büller H.R. |
| |
|
An assessment of surgical thromboprophylaxis in a tertiary care center
|
| Robinson-Cohen C., Tagalakis V., Dubois M., Pilon D. |
| |
|
An association between anti-platelet drug use and reduced cancer prevalence in diabetic patients: results from the vermont diabetes information system
|
| Holmes C.E., Ramos-Nino M.E., Littenberg B. |
| |
|
An ELISA-based assay for alloantibodies against factor VIII in patients with hemophilia A
|
| Yu Z., Zhang L., Zhang W., Zhao Y., Wang Z., Bai X., Ruan C. |
| |
|
An engineered coagulation factor IX with augmented activity: using mouse models to characterize the clotting function in vivo and further evaluate the thrombosis risk
|
| Kao C.Y., Lin C.N., Yu I.S., Lin S.R., Tao M.H., Wu H.L., Shi G.Y., Fang C.C., Lin S.W. |
| |
|
An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and aPTT
|
| Schott U., Rundgren M., Engström M. |
| |
|
An evaluation of thrombotic changes in bereavement
|
| Morel-Kopp M.C., Buckley T., Chen Q., Tofler G., McKinley S., Bartrop R., Ward C.M. |
| |
|
An experimental model to study dissaminated intravacular coagulation in sheep
|
| Siller-Matula J.M., Plasenzotti R., Jilma B. |
| |
|
An exploration of the lived experiences of patients living with chronic idiopathic thrombocytopenic purpura
|
| Ragoonanan V. |
| |
|
An external quality assessment program for the PFA-100
|
| Favaloro E.J., Bonar R., Marsden K. |
| |
|
An in vitro model to visualize and quantify phagocytosis of platelets and vWF
|
| Wu Y.P., van der Wal D.E., de Groot P.G., Akkerman J.W.N. |
| |
|
An in vitro study about the combined antiplatelet effects of cilostazol and aspirin
|
| Alberto M.F., Meschengieser S., Pieczanski P., Rodriguez Moncalvo J., Lazzari M.A. |
| |
|
An inhibitory role of platelet CD109 in platelet function
|
| Matsumoto K., Matsubara Y., Hoshino H., Yokoyama K., Watanabe G., Shibano T., Suzuki N., Ikeda Y., Murata M. |
| |
|
An unusual case of type 2N VWD
|
| Merriman E.G., Laurie A., Smith M. |
| |
|
Analyses of 40K polyethylene glycol used for glycopegylated recombinant human FVIIA
|
| Palm L., Hoeg T.S., Ström J., Malmstrom J., Chen W., Nielsen A.D. |
| |
|
Analysis and characterization of glycopegylated recombinant human FVIIA
|
| Palm L., Jepsen T., Garmer S.F., Malmstrom J., Nielsen A.D., Chen W., Valentin S. |
| |
|
Analysis of fibrin structure and function in man exposed to transient diesel exhaust
|
| Metassan S., Routledge M.N., Lucking A.J., Scott J.A., Mills N.L., Newby D.E., Ariëns R.A.S. |
| |
|
Analysis of intron 1 and intron 22 inversion in factor VIII gene in patients with haemophilia A
|
| Wu J., Li T., Dai J., Ding Q., Wang X., Ding K., Zheng C. |
| |
|
Analysis of lethal outcomes in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) based on long-term follow-up
|
| Reshetnyak T.M., Shtivelband I.B., Alexandrova E.N., Mach E.S., Kondratyeva L.V., Ostryakova E.V., Novikov A.A., Nasonov E.L. |
| |
|
Analysis of the association between the polymorphism PLA1/A2 of the platelet glycoprotein IIB/IIIA gene and the risk of ischemic stroke in young patients
|
| Coelho F.F., Fernandes A.P., Gomes K.B., Miranda C.G., Carvalho M.G., Sabino A.P., Gadelha T. |
| |
|
Analysis of the genetic expression from acute deep venous thrombosis
|
| Rubin M.S., Deckmann A.C., Carazzolle M.F., Parizzi L.P., Pereira G.A.G., Annichino-Bizzacchi J.M. |
| |
|
Analysis of the genetic expression of inflammatory mediators from deep venous thrombosis patients
|
| Rubin M.S., Deckmann A.C., Carazolle M.F., Parizzi L.P., Pereira G.A.G., Annichino-Bizzacchi J.M. |
| |
|
Analytical performance of new and quantitative assays for the diagnosis of antiphospholipid syndrome on a fully automated, chemiluminescent analyzer
|
| Morin K.A., Barry R.G., Guasch J.F., Ruiz N., Puig J., Musial J., Arnout J., Reber G., de Moerloose P. |
| |
|
Angiogenic effect of alternatively spliced and full-length tissue factor inhibition by TFPI
|
| Giannarelli C., Turu M.M., Cimmino G., Fuster V., Badimon J.J. |
| |
|
Angiogenic signaling by Rap1b in endothelial cells involves activation of vascular endothelial growth factor receptor 2 and integrin αvβ3
|
| Chrzanowska-Wodnicka M. |
| |
|
Angiotensin II induces the expression of procoagulant microparticles by human monocytes/macrophages
|
| Cordazzo C., Neri T., Iorio M., Carmazzi Y., Vanacore R., Pedrinelli R., Celi A. |
| |
|
Angiotensin II receptor blockade increases endothelial repair potential in younger adults with severe peripheral arterial disease (PAD)
|
| Levy P.J., Strawn W.B., Brosnihan K.B., Moore L.C., Holbrook J.B., Hansen K.J., Ferrario C.M. |
| |
|
Angiotensin-(1-9) enhances venous thrombosis development in rat by inhibiting fibrinolytic activity
|
| Mogielnicki A., Kramkowski K., Pawlak D., Hermanowicz J.M., Buczko W. |
| |
|
Animal models of the plasma kallikrein/kinin system: modulation of arterial thrombosis
|
| Schmaier A.H. |
| |
|
Anionic lipid domain formation on the nanometer scale
|
| McLean M.A., Denisov I.G., Sligar S.G. |
| |
|
Anionic phospholipids lose their procoagulant properties when incorporated into high-density lipoproteins
|
| Oslakovic C., Krisinger M.J., Andersson A., Jauhiainen M., Ehnholm C., Dahlbäck B. |
| |
|
Annexin V gene involvement in the occurrence of gestational vascular disorders
|
| Tiscia G.L., Colaizzo D., Chinni E., Pisanelli D., Scianname N., Favuzzi G., Margaglione M., Grandone E. |
| |
|
Antagonists of integrin GPIIB/IIIA paradoxically enhance GPVI-induced platelet activation, revealing a feedback signalling pathway from integrin to GPVI involving the protein tyrosine phosphatase PTP1b
|
| Jones M.L., Harper M.T., Aitken E.W., Poole A.W. |
| |
|
Anthropometric and haemostatic cardiovascular risk in young Nigerian semi vegetarians
|
| Awodu O.A., Adeyemi A.A., Omolade O.A., Makinde Y.O., Ajayi O.I., Famodu A.A. |
| |
|
Anthropometric measures of obesity and risk of VTE – the tromso study
|
| Borch K.H., Kufaas-Braekkan S., Mathiesen E., Njolstad I., Wilsgaard T., Stormer J., Hansen J. |
| |
|
Anthropometry and venous thromboembolism: a danish follow-up study
|
| Severinsen M.T., Kristensen S.R., Johnsen S.P., Overvad K. |
| |
|
Anti beta 2 glycoprotein I antibodies at women with pathological pregnancy
|
| Neceva V., Kostovska S., Nikoloska I., Apostolovska R. |
| |
|
Anti-A2 monoclonal antibody enhancing thrombin (and factor Xa)-catalyzed factor VIII activity
|
| Takeyama M., Nogami K., Soeda T., Ogiwara K., Nishiya K., Shima M. |
| |
|
Anti-beta-2glicoprotein I antibodies directed to domain I in patients with antiphospholipid syndrome (APS) and triple laboratory positivity
|
| Banzato A., Pozzi N., Defilippis V., Bison E., Tonello M., Ruffatti A., Pengo V. |
| |
|
Anti-beta-2-glycoprotein-I IgG antibodies and anti-cardiolipin IgG antibodies do not predict thrombosis in patients with a persistent lupus anticoagulant
|
| Koder S., Vormittag R., Zoghlami C., Panzer S., Quehenberger P., Pabinger I. |
| |
|
Antibodies of patients with heparin-induced thrombocytopenia recognize complexes formed by platelet factor 4 and nucleic acids
|
| Jaax M.E., Krauel K., Fürll B., Marschall T., Appel B., Müller S., Fischer S., Preissner K.T., Greinacher A. |
| |
|
Antibody-independent, αIIbβ3-mediated activation of human platelets by unfractionated heparin
|
| Gao C., Boylan B., Fang J., Wilcox D.A., Newman D.K., Newman P.J. |
| |
|
Anticardiolipin and anti-beta 2 glycoprotein 1 antibodies are required for the clinical diagnosis of antiphospholipid syndrome
|
| Gardiner C., Hills J., Machin S.J., Cohen H. |
| |
|
Anticardiolipin antibodies and lupus anticoagulant in children with systemic lupus erythematosus – the North Indian experience
|
| Ahluwalia J., Singh S., Naseem S., Suri D. |
| |
|
Anti-CD20 as alternative to splenectomy in patients with refractory immune thrombocytopenic purpura. Two years follow-up
|
| Alvarez M., Jimenez V., Martin M., Fernandez I., Butta N., Muñoz I., Rivas I., Garcia M., Hernandez F. |
| |
|
Anticoagulant activities of EP42675, synthetic direct thrombin and indirect factor Xa inhibitor
|
| Bal dit Sollier C., Neuhart E., Krezel C., Petitou M., Drouet L. |
| |
|
Anticoagulant mechanisms of antithrombin-heparin studied by TEG
|
| Atkinson H.M., Mewhort-Buist T.A., Berry L.R., Chan A.K.C. |
| |
|
Anticoagulation in a patient with catastrophic antiphospholipid syndrome (APS)
|
| Serre A.F., Ruivard M., Berger M.G., Marquès-Verdier A. |
| |
|
Anticoagulation in childhood arterial ischemic stroke: recent evidence from the international pediatric stroke study and the colorado-and-german collaboration
|
| Goldenberg N.A. |
| |
|
Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency
|
| Davidson S.J., Turner N., Tillyer L. |
| |
|
Anticoagulation prior to diagnostic confirmation in patients with suspected pulmonary embolism
|
| Marchick M.R., Courtney D.M., Kabrhel C., Moore C.L., Nordenholz K.E., Kline J.A. |
| |
|
Anti-dengue NS1 antibody induces heme oxygenase-1 gene expression in endothelial cells
|
| Rahayu P., Naidu S., Rachman A., Immenschuh S., Santoso S. |
| |
|
Anti-diabetic small molecule 1,2,3,4,6-penta-o-galloyl-α-d-glucopyranose inhibits platelet activation by preventing Giα2-mediated signal transduction
|
| Akbar H., Funk K., Wulf S., Perveen R., Cao Y., Chen X. |
| |
|
Antidote reversal of a novel prothrombin aptamer anticoagulant
|
| Bompiani K.M., Oney S., Church F.C., Sullenger B.A. |
| |
|
Anti-fibrogenic effects of the direct thrombin inhibitor dabigatran in lung fibroblasts
|
| Bogatkevich G.S., Silver R.M. |
| |
|
ANTI-GPIIbIIIa-induced acquired thrombasthenia in a patient with sle
|
| Blickstein D., Dardik R., Rosenthal E., Lahav J., Molad Y., Shpilberg O., Inbal A. |
| |
|
Anti-human, anti-bovine thrombin anti-bodies and factor v/va anti-bodies in normal human subjects
|
| Paterson C., Fareed J. |
| |
|
Antihypertensives and new-onset atrial fibrillation: an age-related association
|
| Ma T., Jong G., Tien L. |
| |
|
Antiinflammatory and antiatherogenic effects of dietary supplementation with a combination of marine oil and extra virgin olive oil in apo-E-deficient mice fed an atherogenous diet
|
| Eilertsen K., Elvevoll E., Olsen J., Hoylaerts M., Østerud B. |
| |
|
Anti-inflammatory effect of thrombolytic preparation longolytin
|
| Serebryakova T.N., Sharkova T.S., Podorolskaya L.V., Chromov I.S. |
| |
|
Antiphospholipid antibodies and the risk of myocardial infarction and ischemic stroke in young women
|
| Urbanus R.T., Siegerink B., Roest M., Rosendaal F.R., de Groot P.G., Algra A. |
| |
|
Antiphospholipid antibodies in women with a history of pregnancy-related venous thrombosis (VT) – a population-based case-control study
|
| Bergrem A., Jacobsen E.M., Skjeldestad F.E., Jacobsen A.F., Sandset P.M. |
| |
|
Antiphospholipid antibodies of infants with cerebral events - a unique entity or variant of antiphospholipid syndrome?
|
| Berkun Y., Simchen M., Strauss T., Menashku S., Padeh S., Kenet G. |
| |
|
Antiphospholipid antibodies stimulate human cells via TLR2 and CD14
|
| Satta N., Dunoyer-Geindre S., Boehlen F., Reber G., Kruithof E.K.O., de Moerloose P. |
| |
|
Antiphospholipid syndrome (APS) in a pediatric cohort with venous thromboembolism
|
| Bonduel M., Hepner M., Sciuccati G., Pieroni G., Annetta S.E., Feliú-Torres A., Castañon M., Frontroth J. |
| |
|
Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone
|
| Antonino M.J., Coppolecchia R., Mahla E., Bliden K.P., Tantry U.S., Gurbel P.A. |
| |
|
Antiplatelet effects of parthenolide, the sesquiterpene lactone from feverfew (thanacetum parthenium)
|
| Helinska M., Rozalski M., Rychlik B., Watala C. |
| |
|
Antithrombin (AT) deficiency: effect of perioperative thromboprophylactic approach on venous thromboembolic event (VTE) rate
|
| Sooriyakumar T., Bretherton S., Phillips J.K. |
| |
|
Antithrombin Ala383pro: a new missense variant identified in a patient with venous thrombosis
|
| Tirado I., Borrell M., Llobet D., Coll I., Vallvé C., Fuentes P., Mateo J., Fontcuberta J. |
| |
|
Antithrombin cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
|
| Roldán V., Ordóñez A., Marín F., Zorio E., Soria J.M., Miñano A., España F., González-Conejero R., Pineda J., Estellés A., Fontcuberta J., Vicente V., Corral J. |
| |
|
Antithrombin deficiency: a gap in diagnostics
|
| Fischer R., Heidinger K., Huth-Kühne A., Staritz P., Zimmermann R., Pavlova A., Oldenburg J., Kemkes-Matthes B. |
| |
|
Antithrombin murcia (K241E) reveals a new mechanism for antithrombin deficiency indirectly affecting glycosylation
|
| Martínez-Martínez I., Ordóñez A., Navarro-Fernández J., Pérez-Lara Á., Gutiérrez-Gallego R., Giraldo R., Martínez C., Llop E., Vicente V., Corral J. |
| |
|
Antithrombotic activity of oral heparins in a porcine model
|
| Hiebert L.M., Ping T., Wice S.M. |
| |
|
Antithrombotic and antifibrinolytic effects of platelet protease nexin-1
|
| Boulaftali Y., Adam F., Venisse L., Loyau S., Ollivier V., Alessi M., Bryckaert M., Favier R., Arocas V., Jandrot-Perrus M., Bouton M. |
| |
|
Anti-thrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to current marketed antiplatelet drugs
|
| Ulrichts H., Schoolmeester A., Hoefman S., Lauwereys M., Casteels P., Stanssens P., Baumeister J., Roodt J., de Jaegere P.P.T., Holz J. |
| |
|
Antithrombotic effects of a factor VII antisense oligonucleotide in mice
|
| Crosby J.R., Gao D., Zhao C., Siwkowski A., Zhang H., MacLeod A.R., Monia B.P. |
| |
|
Anti-thrombotic effects of an anti-von Willebrand factor A1 domain aptamer in blood from patients under aspirin and clopidogrel therapy
|
| Arzamendi D., Dandachli F., Ducroq G., Théorêt J. F., Mourad W., Gilbert J., Schaub R., Tanguay J.F., Merhi Y. |
| |
|
Antithrombotic effects of beta2-adrenergic receptor blockade on top of beta1-receptor blockade in patients with acute coronary syndrome or heart failure; a systematic review
|
| de Peuter O.R., Lussana F., Peters R.J., Büller H.R., Kamphuisen P.W. |
| |
|
Antithrombotic profiles of TAK-442, a novel oral factor Xa inhibitor, in venous and arterial thrombosis models
|
| Konishi N., Hiroe K., Shinozawa E., Shofuda K., Matsuda K., Imaeda Y., Fujimoto T., Kubo K., Kawamura M. |
| |
|
Antithrombotic properties of S 35972, a new orally active thrombin inhibitor
|
| Vallez M.O., Gloanec P., De Nanteuil G., Rupin A., Verbeuren T.J. |
| |
|
Antithrombotic prophylaxis for laparoscopic cholecystectomy: a meta-analysis
|
| Becattini C., Rondelli F., Manina G., Noya G., Agnelli G. |
| |
|
Antiviral treatment of HCV infected young haemophiliacs – an update of 16 years experience
|
| Koehler-Vajta K., Froesner G., Zachoval R. |
| |
|
Anti-Xa monitoring is required in pregnant women on low molecular weight heparin (LMWH)
|
| Simpson V.M.A., Pescott M., Peebles D., Cohen H. |
| |
|
Anti-Xa:anti-IIa ratio varies with age and UFH concentration in children
|
| Newall F.H., Ignjatovic V., Johnston L., Lane G., Summerhayes R., Monagle P. |
| |
|
Anucleate platelets generate functional progeny
|
| Schwertz H., Koster S., Kahr W.H.A., Kraiss L.W., Zimmerman G.A., Weyrich A.S. |
| |
|
APCC in combination with FVIII potentiate in vitro thrombin production in inhibitor plasma
|
| Klintman J., Astermark J., Ekman M., Berntorp E. |
| |
|
APCC versus RFVIIA in treatment of hemophilia patients with inhibitors: a structured review of the pharmacoeconomic literature
|
| Hay J.W., Zhou Z. |
| |
|
Apixaban in patients with metastatic cancer: a randomized phase II feasibility study
|
| Liebman H., Levine M.N., Deitchman D., Julian J., Escalante C.P., O’Brien M.C., Ramirez L.M., Weise-Kelly L., Solymoss S. |
| |
|
Apo(a) increases clot stability in transgenic mice
|
| Hoover-Plow J.L., Hart E., Saraniti J. |
| |
|
Apolipoprotein E receptor 2 is a platelet receptor for coagulation factor XI
|
| White-Adams T.C., Berny M.A., Tucker E.I., Pang J., Gailani D., Urbanus R.T., Groot de P.G., Gruber A., McCarty O.J.T. |
| |
|
Apoptotic process is involved in the early phase of megakaryopoiesis, but not in platelet production from megakaryocytes
|
| Kozuma Y., Ninomiya H., Kono T., Mukai H.Y., Kojima H. |
| |
|
Apparent overutilization of thrombophilia screening panels: an analysis of physician ordering patterns at an urban academic medical center
|
| Patel K.P., Somma J., Rose H., Sussman I.I., Rand J.H. |
| |
|
Application of dynamic light scattering to the measurement of microparticles
|
| Harrison P., Dragovic R., Albanyan A., Lawrie A.S., Murphy M., Sargent I. |
| |
|
Application of low molecular-weight heparin in pregnant women
|
| Vorobiova E., Pargalava N., Bokuchava M., Akhvlediani M. |
| |
|
Application of thrombelastography¯ for monitoring haemostatic change in rats with lipopolysaccharide-induced disseminated intravascular coagulation
|
| Tsai H., Liao M., Liaw W., WU C. |
| |
|
Appropriate VTE prophylaxis, compared with partial VTE prophylaxis, leads to lower VTE recurrence and cost in US medical patients
|
| Amin A.N., Hussein M., Battleman D., Lin J., Stemkowski S., Merli G.J. |
| |
|
Are citrated partial-draw polymer collection tubes adequate for basic coagulation tests?
|
| Toulon P.A., Eschvege V., Dreyfus M., Boutekedjiret T., Proulle V. |
| |
|
Are platelets phagocytes or covercytes? An ultrastructural study of interaction between Porphyromonas gingivalis, an oral bacterium and human platelets
|
| Suzuki H., Li X., Nakamura H., Inoue Y., Chen Y., Umeda M., Iwai T. |
| |
|
Are TEG pattern interpretations reliable?
|
| Exner T., Parsi K. |
| |
|
Arecoline induced cytotoxicity, il-8 production and gene expression in human endothelial cells
|
| Jeng J.H., Chang M.C. |
| |
|
Argatroban anticoagulant therapy with low initial dosage in cardiovascular disease patients with heparin-induced thrombocytopenia
|
| Miyata S., Yamamoto H., Ohkita Y., Yamada N., Shimokawa T., Myojin K., Tomoike H. |
| |
|
Arnica montana has no effect on coagulation and bleeding time in vivo
|
| Mahlangu J.N., Mahlangu J.N., Saunders B., Reaves A., Nkujani T., Basson M. |
| |
|
Aronia melanocarpa extract may lead to platelet activation when used at high concentrations
|
| Golanski J., Helinska M., Rozalski M., Kraszula L., Watala C. |
| |
|
Arrestin-2: regulating platelet responses to agonist
|
| Woulfe D.S., Li D., Chavez M. |
| |
|
Arsenic trioxide inhibits invasive potential of NB4 cells through down regulation of Annexin 2
|
| Bao H., Ruan J., Jiang M., Ruan C. |
| |
|
Arterial thrombosis in patients with antiphosholipid syndrome
|
| Swadzba J., Matyja-Bednarczyk A., Iwaniec T., Bulikova A., Musial J. |
| |
|
Arteriovenous (AV) fistula thrombosis and thrombophilia
|
| Varughese J.I., Sandhu M., Sachdev S., Palekar S., Cohen A., Eisenberger A. |
| |
|
Aspirin and cardiovascular disease: a cyclooxygenase-independent mode of action
|
| Ajjan R.A., Standeven K.F., Naseem K., Khanbhai M., Phoenix F., Gersh K., Weisel J.W., Ariens S. R.A., Kearney M.T., Grant P.J. |
| |
|
Aspirin resistance; an investigation and explanation
|
| McCall M., Tedesco A.F., Peace A., Foley D., Cox D. |
| |
|
Aspirin responsiveness measured by COX-1 specific and COX-1 non-specific methods in healthy subjects: clarifying the debate on aspirin ‘resistance’
|
| Antonino M.J., Bliden K.P., Coppolecchia R., Gesheff M., Gurbel P.A., Singla A., Lawal L., Kotev S., Tantry U.S., Gurbel P. |
| |
|
Aspirin, 110 years later
|
| Patrono C., Rocca B. |
| |
|
Assay dependent variations in the USP potency standardized unfractionated heparins
|
| Gray A., Hoppensteadt D., Myers L., Iqbal O., Adiguzel C., Fareed J. |
| |
|
Assay of procoagulant microparticles with a calibrated automated thrombogram
|
| Owen B.A., Heit J.A. |
| |
|
Assembly of the prothrombinase complex in the presence of TSP1 on the fibroblast surface induces upregulation of CTGF by two separate signaling pathways
|
| Rico M.C., Rough J.J., Manns J.M., Kunapuli S.P., DeLa Cadena R.A. |
| |
|
Assesment of thrombotic risk in patients with PV/ET by TEG: judicious use of low dose aspirin in thrombosis prophylaxis
|
| Kuperman A., Akria L., Braester A. |
| |
|
Assessing immune response after repeated avidin reversal of the anti-Xa activity of idrabiotaparinux (biotinylated idraparinux)
|
| Paty I., Cortez P., Trellu M., Sultan E. |
| |
|
Assessing the benefits APCC prophylaxis in hemophilia patients with inhibitors
|
| Valentino L.A. |
| |
|
Assessing the function of clotting system and searching for prognostic tests in liver cirrhosis
|
| Kolaitis N.I., Oikonomou A., Vartholomatos G., Baltayiannis G., Tsianos E.V. |
| |
|
Assessing the uptake of national initiatives to improve venous thromboembolism patient care in the UK
|
| Arya R., McManus A., Paneesha S., Scriven N., Nokes T., Farren T., Nieland A., Rose P., Bacon S., O’Shaughnessy D. |
| |
|
Assessment of clopidogrel and aspirin therapy using remote platelet testing
|
| Fox S.C., May J.A., Shah A., Neubert U., Heptinstall S. |
| |
|
Assessment of endothelial dysfunction in patients of different age with chronical renal failure
|
| Vlasova E., Vasilenko I., Samoylenko V., Suslov V., Vaschuk I. |
| |
|
Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor
|
| Perzborn E., Hardwardt M., Samama M.M. |
| |
|
Assessment of genotype-phenotype relationship for six common platelet polymorphisms in 286 healthy subjects
|
| Martínez C., Antón A.I., Corral J., Quiroga T., Panes O., Lozano M.L., González-Conejero R., Teruel R., Navarro-Núñez L., Pereira J., Navarro N., Mezzano D., Vicente V., Rivera J. |
| |
|
Assessment of platelet function in normal adults: gender and race differences in platelet aggregation and ATP release
|
| Stein S.F., Rice A., Lindstrom K., Miller C.H. |
| |
|
Assessment of pulmonary hypertension in patients affected by pulmonary embolism (PE)
|
| Barchitta A., Ruzza L., Tosato F., Pessina A.C., Pengo V. |
| |
|
Assessment of quality control and accuracy of portable coagulometers for monitoring oral anticoagulant treatment in anticoagulation clinic
|
| Paniccia R., Poli D., Antonucci E., Pagliuca M., Lami D., Ricci I., Alessandrello Liotta A., Prisco D., Abbate R. |
| |
|
Assessment of race, gender and mortality from a large nationwide sample of patients admitted for pulmonary embolism in the United States
|
| Courtney D.M., Khare R.K. |
| |
|
Assessment of responsiveness to antiplatelet therapy by light transmittance aggregometry: an adjustment for platelet count is not necessary
|
| Schwonberg J., Linnemann B., Prochnow S., Mani H., Lindhoff-Last E. |
| |
|
Assessment of the effect of AR-H067637 on the ETP as obtained by calibrated automated thrombinoscopy
|
| Wagenvoord R.J., Deinum J., Elg M., Hemker C. |
| |
|
Assessment of thrombin generation in mild haemophilia a with factor VIII assay discrepancy
|
| Gilmore R.M., Harmon S., Gannon C., Byrne M., White B., O’Donnell J.S., Jenkins P.V. |
| |
|
Assisted reproduction (AR) and incidence thrombophilie
|
| Krcova V., Oborna I., Brezinova J., Hlusi A., Slavik L., Ulehlova J. |
| |
|
Association between aspirin resistance and platelet function tests
|
| Genc S., Saka B., Eroglu H., Omer B., Erten N., Tascıoglu C. |
| |
|
Association between C-reactive protein and arterial ischemic stroke in children
|
| Coen Herak D., Milos M., Lenicek Krleza J., Zrinski Topic R., Dodig S., Duranovic V., Zadro R. |
| |
|
Association between etiology of cirrhosis, child's classification, presence of ascites and conventional coagulogram, and the immediate preoperative thromboelastographic profiles in patients submitted to liver transplantation
|
| Ribeiro D.D., Ferrari T.C.A., Lima A.S., Rocha P.R.S. |
| |
|
Association between factor XII C46T polymorphism and thrombotic diseases in Taiwan and its particular role in male patients
|
| Yu Y.B., Gau J.P., Chen C.C., You J.Y., Hsu H.C., Hong Y.C., Liu C.Y., Chen P.M., Lee T.S., Tzeng C.H. |
| |
|
Association between genetic variation at the ADAMTS13 locus and ischemic stroke
|
| Hanson E., Jood K., Nilsson S., Blomstrand C., Jern C. |
| |
|
Association between homocysteine, anticardiolipin and antibeta2 glycoprotein-I antibodies in patients with coronary artery disease
|
| Smirnova O.A., Shmeleva V.M., Kobilyanskaya V.A., Papayan L.P. |
| |
|
Association between platelet reactivity and genetic variations in Japanese general population
|
| Okada H., Sakata T., Kokubo Y., Okamura T., Miyata T. |
| |
|
Association of anti-β2GPI domain I IgG and resistance to annexin A5 with obstetrical antiphospholipid syndrome: evidence for a specific mechanism in a patient subset
|
| Hunt B.J., Wu X., de Laat B., Arslan A.A., Parmar K., Stuart-Smith S., Rand J.H. |
| |
|
Association of blood cellular markers with carotid plaque size and composition
|
| Matijevic N., Wu K.K., Howard A.G., Wasserman B., Wang W., Folsom A.R., Sharrett R. |
| |
|
Association of coagulation and inflammation related genes and factor 7 levels with ischemic stroke: the cardiovascular health study
|
| Zakai N.A., Reiner A.P., Lang L.A., Longstreth W.T., O’Meara E., Kelley J., Fornage M., Nickerson D.A., Cushman M. |
| |
|
Association of endogenous thrombin potential (ETP) with coronary artery disease. an angiography-based study
|
| Martinelli N., Olivieri O., Campostrini N., Castagna A., Friso S., Pizzolo F., Guarini P., Annarumma L., Busti F., Corrocher R., Girelli D. |
| |
|
Association of factor VII hypercoagulant activity with insulin resistance in coronary heart disease
|
| karatela R.A., Sainani G. |
| |
|
Association of haemostatic and inflammatory markers with future ischemic cardiovascular events in patients with peripheral arterial disease – initial laboratory results of the prevention of ischemic events in patients with peripheral arterial disease (PID)
|
| Bedencic M., Blinc A., Bozic Mijovski M., Stegnar M., Kozak M., Sabovic M., Poredos P., Kravos A., Barbic-Zagar B., Pohar-Perme M., Stare J. |
| |
|
Association of influenza vaccination with reduced risk of venous thromboembolism
|
| Emmerich J., Zhu T., Carcaillon L., Martinez I., Cambou J., Kyndt X., Guillot K., Vergnes M., Scarabin P. |
| |
|
Association of single nucleotide polymorphisms (SNP) in methionine synthase (MTR) and betaine-homocysteine methyl transferase (BHMT) genes with coronary artery disease (CAD): role of dietary factors on homocysteine
|
| Mukherjee M.S., Singh P.R., Shetty K.R. |
| |
|
Association of soluble tweak with coronary artery disease in the Asian Indian population
|
| Rao V.S., Natesha B.K., Niladri S., Sridhara H., Shibu J., Kakkar V.V. |
| |
|
Association of the genetic polymorphisms of the pituitary growth hormone and its receptor with premature coronary artery disease in Asian Indians
|
| Maitra A., Dash D., John S., Sannappa P.R., Nagaraj S., Shanker J., Rao V.S., Sridhara H., Kakkar V.V. |
| |
|
Association of the single nucleotide polymorphism RS2227589 in the SERPINC1 gene with inherited antithrombin deficiency
|
| Jochmans K., Orlando C., Lissens W., Liebaers I., De Waele M. |
| |
|
Association of the VEGF polymorphisms and haplotypes with the risk of osteoporotic vertebral compression fractures in postmenopausal women
|
| Kim N., Chung Y., Hong S., Shin D., Lee J. |
| |
|
Association of vasopressin induced impairment of microcirculation with a drop-off in adamts13 activity in patients with septic shock
|
| Claus R.A., Klinzing S., Reuken P., Bockmeyer C.L., Schuerholz T., Reinhart K., Marx G., Losche W., Bauer M. |
| |
|
Association study between variants in GAS6-TAM genes and atheroma carotid plaque
|
| Hurtado B., Abasolo N., Muñoz X., Garcia N., Krupinski J., Garcia de Frutos P., Sala N. |
| |
|
Associations between the von Willebrand factor gene (VWF) variant C.2771G > A (P.R924Q), von Willebrand factor antigen (VWF:Ag) and FVIII activity (FVIII:C) levels and its role as a risk factor for type 1 von Willebrand disease (VWD)
|
| Hickson N., Hampshire D.J., Winship P.R., James P.D., Peake I.R., Goodeve A.C., EU-VWD and ZPMCB-VWD Study Groups |
| |
|
Associations of circulating natural killer cells with cardiovascular disease risk factors: the multi-ethnic study of atherosclerosis (MESA)
|
| Jenny N.S., Doyle M., Kronmal R., Huber S., Psaty B.M., Tracy R.P. |
| |
|
Associations of thrombin generation with risk of cardiovascular disease in the glasgow monica study
|
| Smid M., Woodward M., Rumley A., van Oerle R., Spronk H.M.H., ten Cate H., Lowe G. |
| |
|
Asymptomatic MRI brain abnormalities in patients with thalassemia intermedia
|
| Taher A., Musallam K.M., Nasreddine W., Beydoun A. |
| |
|
Asymptomatic venous thromboembolism in cancer patients: prevalence and consequence
|
| Douma R.A., Kok M.G.M., Verberne L.M., Kamphuisen P.W., Büller H.R. |
| |
|
Atherosclerosis-associated LY-6Chi blood monocytosis impairs wound healing in mice with myocardial infarction
|
| Panizzi P.R., Swirski F.K., Figueiredo J., Waterman P., Sosnovik D.E., Aikawa E., Libby P., Pittet M., Weissleder R., Nahrendorf M. |
| |
|
Atherosclerotic lesions development is not prevented in the GPIbbeta-/-ApoE-/- double knockout mice
|
| Strassel C., Hechler B., Bull A., Freund M., Cazenave J., Gachet C., Lanza F. |
| |
|
Atorvastatin reduces persistent platelet TXA2 synthesis in aspirin-treated patients with acute myocardial infarction
|
| Santos M.T., Fuset M.P., Ruano M., Moscardó A., Valles J. |
| |
|
Atorvastatin treatment increases the liquid order of platelet membranes
|
| Labarthe B., Maguy A., Gallo R., Theroux P., Bonnefoy A. |
| |
|
Attenuated elevation of sP-selectin in patients with recent myocardial infarction is related to bleeding events during antithrombotic treatment
|
| Christersson C., Oldgren J., Wallentin L., Siegbahn A. |
| |
|
Attitudes towards treatment with vitamin-k antagonists in relation to personality traits in patients on stable oral anticoagulant therapy
|
| Felten M., Harenberg J., Frölich L., Weiss C. |
| |
|
Audit of the clinical use of fresh-frozen plasma in umbria: study design and results
|
| Basileo M., Marchesi M., Marchesini E., Materazzi M., Germani A., Rocchetti L., Silvani C., Iorio A. |
| |
|
Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis
|
| Cesarman-Maus G.N., Barinagarrementería F., Villa R., García-Latorre E., Reyes E., Hajjar K.A., Cantu-Brito C. |
| |
|
Autologous plasma for the study of anaphylatoxin kinetics in man
|
| Schott U., Norda R. |
| |
|
Automated anti-factor IIa assay for monitoring unfractionated heparin (UFH)
|
| Summerhayes R., Ignjatovic V., Newall F., Monagle P. |
| |
|
Automatization of genetic analysis: Factor V Leiden, F2G20210A, F12C46T and MTHFRC677T by real time PCR
|
| Coll I., Tirado I., Martínez-Sánchez E., Souto J., Orantes V., Fontcuberta J. |
| |
|
Autotaxin/lysophosphatidic acid axis: in vivo evidence for a role in obesity predisposition
|
| Federico L., Liu S., Muller P., Mills G.B., Morris A.J., Smyth S.S. |
| |
|
Availability of peripheral inserted central catheters in severe hemophilia patients
|
| Park Y., Park J. |
| |
|
AVE5026: a new hemisynthetic ultra low molecular weight heparin with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis
|
| Gray A., Hoppensteadt D., Jeske W., Walenga J.M., Fareed J. |
| |
